Drugs / Zn-Telomir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07581314 | Oct 2026 → May 2027 expected | triple-negative breast carcinoma | Telomir Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zn-Telomir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07581314 ↗ |
| Action | Inhibit | “inhibits iron-dependent KDM enzymes” NCT07581314 ↗ |
| Modality | Small molecule | “Zn-Telomir is an oral small molecule” NCT07581314 ↗ |
| Route | Oral | “Participants receive oral Zn-Telomir once daily” NCT07581314 ↗ |